China woman suffers brain haemorrhage, in coma after sunbathing to improve health
The incident recently unfolded in Zhejiang province, southeastern China, when the woman, surnamed Wang, tried a traditional Chinese medicine (TCM) remedy she had heard about.
The remedy apparently said that 'sunbathing your back can warm the yang energy, dispel dampness and cure illnesses'.
Around noon, Wang lay face-down in an open area outside her home for two hours.
Experts say that when it comes to sunbathing, keeping strict control over the amount of exposure to the sun is vital. Photo: Shutterstock
However, shortly after returning indoors, she collapsed and lost consciousness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
8 hours ago
- South China Morning Post
How a classic poem by Chinese poet Wang Bo sums up my feelings over good friend's death
I am writing this with great sadness. A very good friend of mine died last week in Hong Kong. He was only 65. He had been enjoying his retirement from the Hong Kong civil service, travelling overseas every other month, when he was diagnosed with stage-four lung cancer two years ago. Despite the devastating and totally unexpected diagnosis – he never smoked and led an active, healthy life – he remained sanguine about his condition and complied with all the treatments prescribed. In the two years after his diagnosis, he still travelled and lived life to the fullest. It was only in the last few months that his condition suddenly deteriorated. I had a video call with him two days before he passed. He could not speak, but he recognised me. I could not speak because I was in tears. I had known him for close to 13 years. Both of us shared a wicked sense of humour, and we had many laughs over countless drinks and meals together.
South China Morning Post
10 hours ago
- South China Morning Post
Hong Kong public healthcare moving on right path: outgoing Hospital Authority head
The Hospital Authority's outgoing chief executive has said Hong Kong public hospitals are on the right path in terms of finances, manpower and infrastructure, with his term as the organisation's top man being a 'complete and abundant' experience. Dr Tony Ko Pat-sing, who will retire by the end of the month, described his past six years as a 'joyful time' despite having to overcome challenges brought by anti-government protests and the Covid-19 pandemic. 'I feel reassured,' Ko said on Thursday. 'I feel our financial resources are stable, manpower is fine, our infrastructure – system, software, hardware and hospitals expansion plan – I think all are in place. 'I view my six-year term as complete and abundant, and I feel joyful about it.' Staff shortages are a long-standing issue in public hospitals, but Ko said that healthcare manpower grew by about 10 per cent compared with when he assumed office in 2019. Currently, there are about 320 non-locally trained doctors from more than 10 jurisdictions working in the city's public hospitals. More overseas-trained nurses have started to join, and the authority is planning to hire allied health professionals trained outside Hong Kong.
South China Morning Post
a day ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
